Investment analysts at StockNews.com started coverage on shares of Actinium Pharmaceuticals (NYSE:ATNM – Get Rating) in a report released on Thursday. The brokerage set a “sell” rating on the stock.
Actinium Pharmaceuticals Price Performance
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
Featured Stories
- Get a free copy of the StockNews.com research report on Actinium Pharmaceuticals (ATNM)
- 5 Best Bank ETFs to Buy Now
- How to Invest in Telehealth and Telemedicine Stocks
- Target’s Guidance Looms Over The MarketÂ
- Want Clean Energy? Siemens May Be Pointing To A Breakout
- Up Over 2,600% in 5 Years, Wall Street Still Calls Celsius a Buy
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
